Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.

Current standard adjuvant therapies for early breast cancer include tamoxifen and chemotherapy, depending on the disease prognosis and menopausal status. Luteinizing hormone-releasing hormone (LHRH) analogues offer a different approach to the management of early breast cancer in pre- and perimenopau...

Descripción completa

Detalles Bibliográficos
Autor principal: Jonat, W.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062750/
https://www.ncbi.nlm.nih.gov/pubmed/9741781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062750/
https://www.ncbi.nlm.nih.gov/pubmed/9741781

Ejemplares similares